Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cytrx Corp (CYTR)

Cytrx Corp (CYTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 8,410
  • Shares Outstanding, K 33,638
  • Annual Sales, $ 250 K
  • Annual Income, $ -12,710 K
  • 60-Month Beta 1.88
  • Price/Sales 33.64
  • Price/Cash Flow N/A
  • Price/Book 0.50
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.13
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/22/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.249 on 03/07/08
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2100 +16.67%
on 11/18/19
0.3195 -23.32%
on 12/02/19
-0.0500 (-16.95%)
since 11/08/19
3-Month
0.2100 +16.67%
on 11/18/19
0.4000 -38.75%
on 10/30/19
-0.0670 (-21.47%)
since 09/10/19
52-Week
0.2100 +16.67%
on 11/18/19
0.7789 -68.55%
on 03/20/19
-0.3150 (-56.25%)
since 12/10/18

Most Recent Stories

More News
CytRx Corporation Reports Second Quarter 2019 Financial Results

LOS ANGELES , Aug. 9, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today announced financial...

CYTR : 0.2450 (-2.00%)
CytRx Corporation Reports Second Quarter 2019 Financial Results

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today announced financial results for the second quarter ended June 30,...

CYTR : 0.2450 (-2.00%)
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C

LOS ANGELES , July 30, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today highlighted that...

CYTR : 0.2450 (-2.00%)
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today highlighted that following a positive meeting with the U.S. Food...

CYTR : 0.2450 (-2.00%)
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

LOS ANGELES , July 22, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol licensee...

CYTR : 0.2450 (-2.00%)
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has completed enrollment...

CYTR : 0.2450 (-2.00%)
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office...

CYTR : 0.2450 (-2.00%)
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation

LOS ANGELES , June 26, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued...

CYTR : 0.2450 (-2.00%)
Delisting of Securities of FTD Companies, Inc., Kaixin Auto Holdings (Warrant Only), CytRx Corporation, and Insys Therapeutics, Inc. from The Nasdaq Stock Market

The Nasdaq Stock Market announced today that it will delist the common stock of FTD Companies, Inc. FTD Companies, Inc.'s stock was suspended on June 13, 2019 and has not traded on Nasdaq since that time....

CYTR : 0.2450 (-2.00%)
NDAQ : 104.61 (-0.03%)
CytRx Corporation to Commence Trading on OTCQB Venture Market

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will commence trading on the OTCQB Venture Market as of Tuesday,...

CYTR : 0.2450 (-2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CYTR with:

Key Turning Points

2nd Resistance Point 0.2583
1st Resistance Point 0.2517
Last Price 0.2450
1st Support Level 0.2417
2nd Support Level 0.2383

See More

52-Week High 0.7789
Fibonacci 61.8% 0.5616
Fibonacci 50% 0.4945
Fibonacci 38.2% 0.4273
Last Price 0.2450
52-Week Low 0.2100

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar